Dolutegravir safe and highly effective in older children
Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed
Tenofovir alafenamide PrEP protects monkeys from infection, but rectal and vaginal levels in humans may be too low
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity
PopART trial shows feasibility of reaching 90-90-90 targets for testing and treatment coverage in Zambia and South Africa
Botswana close to reaching the 90-90-90 testing and treatment targets
Cotrimoxazole prophylaxis provides no benefit for HIV-exposed uninfected children
Partner notification feasible and effective in African settings
Very high levels of chemsex and ‘slamsex’ seen in HIV-positive men attending English/Welsh HIV clinics
